Prevention and early detection of vascular complications of diabetes
Open accessAbstract
Diabetes reduces life expectancy by five to 10 years.Premature cardiovascular disease is the most common cause of morbidity and mortality, but the microvascular complications specific to diabetes (box 1) are also contributory factors.Diabetes is the most common reason for renal replacement therapy worldwide, the most common cause of blindness in the under 65s, and the most common cause of non-traumatic amputation.With our current knowledge, most of these devastating events could be prevented or delayed, or their impact minimised.This review focuses on the prevention, early detection, and initial management of the vascular complications of diabetes in adults.An appendix, extra references, and extra figures are on bmj.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Rapid action can prevent or delay the onset of chronic complications of diabetes.
“It is important to detect the development of complications early enough, as rapid action can prevent or delay the onset of chronic complications (Marshall & Flyvbjerg, 2006).”
From Artificial intelligence based prediction models for individuals at risk of multiple diabetic complications: A systematic review of the literature (2022) · cites this paper as Marshall & Flyvbjerg, 2006
The Summary points and “How do I detect and screen for complications?” say that early detection allows prompt intervention that may prevent or delay end-stage disease. They do not say that intervention after complications are detected prevents the onset of chronic complications themselves. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664 · see citing works
Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion
Martin, C. L., Albers, J., Herman, W. H., Cleary, P., Waberski, B., Greene, D. A., Stevens, M. J., & Feldman, E. L. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1549 · Cited by 350 · see citing works
Costa, J., Borges, M., David, C., & Carneiro, A. V. (2006) · BMJ · doi:10.1136/bmj.38793.468449.ae · Cited by 340 · see citing works
Flagged first, then by citations
Research works printed but not linked: 21
- Jonsson B. CODE-2 advisory board. Revealing the cost of type II diabetes in Europe. Diabetologia 2002;45:S5-12.
- Laing SP, Swerdlow AJ, Slater SD, Botha JL, Burden AC, Waugh NR, et al. The British Diabetic Association cohort study II: cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabetic Med 1999;16:466-71.
- Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004;82:844-51.
- Rossing P. The changing epidemiology of diabetic microangiopathy in type 1 diabetes. Diabetologia 2005;48:1439-44.
- Van Dijk PC, Jager KJ, Dtengel B, Gronhagen-Riska C, Feest TG, Briggs JD. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). Kidney Int 2005;67:1489-99.
- Tesfaye S, Kempler P. Painful diabetic neuropathy. Diabetologia 2005;48:805-7.
- Boulton AJM, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet 2005;366:1719-24.
- Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 2004;25:971-1010.
- Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes 2005;54:1615-25.
- The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
- UK Prospective Diabetes Study. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-53.
- Writing Team for the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the epidemi- ology of diabetes interventions and complications (EDIC) study. JAMA 2003;290:2159-67.
- Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Inten- sive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53.
- UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ 1998;317:703-13.
- Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al, ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethazide as required, in the Anglo-Scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
- Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high- risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
- Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Liv- ingstone SJ, et al, CARDS Investigators. Primary prevention of cardiovas- cular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo- controlled trial. Lancet 2004;364:685-96.
- Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al, FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.
- Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multi- factorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.
- Reiber GE, Raugi GJ. Preventing foot ulcers and amputations in diabetes. Lancet 2005;366:1676-7. doi 10.1136/bmj.38922.650521. · DOI
- Additional educational resources Diabetes UK (www.diabetes.org.uk) American Diabetes Association (www.diabetes.org) International Diabetes Federation Clinical Guidelines Task Force. Global guidelines for type 2 diabetes. Brus- sels: International Diabetes Federation, 2005 (www.IDF.org) European Union-Austrian conference on prevention of type 2 diabetes (www.diabetesconference.at) The Finnish development programme for the prevention and care of diabetes in Finland (www.diabetes.fi/english/ programme) National service framework for renal services part 2. Chronic kidney disease, acute renal failure and end of life care. London: Department of Health 2005 (www.dh.gov.uk/PublicationsAndStatistics/ Publications/PublicationsPolicyAndGuidance/ PublicationsPAmpGBrowsableDocument/fs/ en?CONTENT_ID = 4102941&chk = aKHxDl) National Screening Committee. Diabetic retinopathy screening workbook: guidance on setting up a systematic programme (www.nscretinopathy.org.uk) Quality Outcomes Framework. Results for England 2004/5 (www.icservices.nhs.uk)
Cited by
Sorted by citations
From pre-diabetes to diabetes: diagnosis, treatments and translational research
Khan, R., Chua, Z., Tan, J., Yang, Y., Liao, Z., & Zhao, Y. (2019) · Medicina · doi:10.3390/medicina55090546 · Cited by 484 · see citing works
Epigenetic phenomena linked to diabetic complications
Pirola, L., Balcerczyk, A., Okabe, J., & El-Osta, A. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.188 · Cited by 239 · see citing works
Chiu, C.-J., & Wray, L. A. (2011) · Annals of Behavioral Medicine · doi:10.1007/s12160-010-9226-0 · Cited by 84 · see citing works
Helmink, J. H., Meis, J. J., de Weerdt, I., Visser, F. N., de Vries, N. K., & Kremers, S. P. (2010) · International Journal of Behavioral Nutrition and Physical Activity · doi:10.1186/1479-5868-7-49 · Cited by 64 · see citing works
Scott, I. U., Jackson, G. R., Quillen, D. A., Larsen, M., Klein, R., Liao, J., Holfort, S., Munch, I. C., & Gardner, T. W. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.93 · Cited by 59 · see citing works
van Son, J., Nyklíček, I., Nefs, G., Speight, J., Pop, V. J., & Pouwer, F. (2015) · Journal of Behavioral Medicine · doi:10.1007/s10865-014-9592-3 · Cited by 42 · see citing works
“People living with diabetes face several challenges, e.g., managing medications and coping with the prospect of longterm complications, such as retinopathy, neuropathy, kidney damage, and cardiovascular disease (Marshall & Flyvbjerg, 2006).”
BackgroundGosak, L., Martinović, K., Lorber, M., & Stiglic, G. (2022) · Journal of Nursing Management · doi:10.1111/jonm.13894 · Cited by 24 · see citing works
“It is important to detect the development of complications early enough, as rapid action can prevent or delay the onset of chronic complications (Marshall & Flyvbjerg, 2006).”
Background
- Authors
- Marshall, S. M., & Flyvbjerg, A.
- Affiliations
- Newcastle University (GB)
- Aarhus University (DK)
- Corresponding author
- Marshall, Sally M
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2006-08-31
- Volume
- 333
- Issue
- 7566
- Pages
- 475-480
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2000056219
- Cited by
- 237
- References
- 3
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 11 · 2023: 8 · 2022: 15 · 2021: 10 · 2020: 14 · 2019: 9 · 2018: 6 · 2017: 10 · 2016: 14 · 2015: 7 · 2014: 17 · 2013: 17 · 2012: 16
- FWCI
- 9.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- BMJ (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- diabetes mellitus, vascular complications, microvascular complications, cardiovascular disease, prevention, early detection, diabetic nephropathy, diabetic retinopathy, diabetic foot, amputation, renal replacement therapy
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Diabetic Nephropathies, Diabetic Neuropathies, Diabetic Retinopathy, Humans, Hyperlipidemias, Hypertension, Mass Screening, Risk Factors, Early Diagnosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
